Responding With Evidence and Access for Childhood Headaches

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Children's Hospital Medical Center, Cincinnati
Study ID
NCT05889624
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
10 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • CBT — BEHAVIORAL
    During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 "booster" CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes.
  • Amitriptyline — DRUG
    During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).

Study Details

This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.

Key Dates

Start date
Aug 22, 2023
Status verified
Mar 2026
Primary completion
Jul 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CBT while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline)
    This intervention consists of Cognitive Behavioral (CBT), a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation, activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements. This arm will also take a daily oral dose of Amitriptyline, which will be clinically prescribed and managed by the patient's headache provider.
  • Experimental: CBT alone
    This intervention arm consists of 6 Cognitive Behavioral Therapy (CBT), a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation, activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.

Primary Outcome Measure

Change in number of headache days [ Time Frame: baseline to weeks 4-8 to weeks 20-24 (post treatment) ]

Central Contacts

Locations (15)

FacilityCityStateZIPSite coordinators
University of Alabama at Birmingham Children's of AlabamaBirminghamAlabama35233
Julio Sebastian Domingo
205-638-6821
Scott Turner, DNP (PRINCIPAL_INVESTIGATOR)
Phoenix Children's Hospital - Barrow Neurological InstitutePhoenixArizona85016-7710
Reena Rastogi, Md (PRINCIPAL_INVESTIGATOR)
University of California San FranciscoSan FranciscoCalifornia94115
Hannah Shapiro, MD (PRINCIPAL_INVESTIGATOR)
University of Colorado/Children's Hospital ColoradoAuroraColorado80045
Theo Greiner
Marcy Yonker, MD (PRINCIPAL_INVESTIGATOR)
Nemours Children's Health SystemWilmingtonDelaware19810
Jessica Rayfield
302-651-6979
Judy Adelizzi-Delany, DNP (PRINCIPAL_INVESTIGATOR)
Clinical Integrative Research Center of Atlanta, IncAtlantaGeorgia30328
Jazmine Roman
678-528-0961
Frank Berenson, MD (PRINCIPAL_INVESTIGATOR)
Chaouki Khoury, MD (PRINCIPAL_INVESTIGATOR)
University of Louisville Health/NortonLouisvilleKentucky40292
Lauren Evansczyk
Elizabeth Doll, MD (PRINCIPAL_INVESTIGATOR)
Louisiana State Univ/Children's Hospital of New OrleansNew OrleansLouisiana70118-5720
Kathryn Peneguy
Rashmi Rao, MD (PRINCIPAL_INVESTIGATOR)
Dent Neurological InstituteAmherstNew York14226
Rebecca Hogan
716-558-5670
Jennifer McVige, MD (PRINCIPAL_INVESTIGATOR)
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
Paula LaFollette
513-636-1840
Joanne Kacperski, MD (PRINCIPAL_INVESTIGATOR)
Nationwide ChildrensColumbusOhio43205
Colin Peachey
Ann Pakalnis, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104
Blanca Marquez de Prado
267-602-9784
Christina Szperka, MD (PRINCIPAL_INVESTIGATOR)
University of Tennessee Health Science Center/ LeBonheur Children's HospitalMemphisTennessee38103
Ankita Gosh, MD (PRINCIPAL_INVESTIGATOR)
Dell Children's Hospital-UT HealthAustinTexas78712
Valerie Cuellar
512-324-0000
Sara Pavitt, MD (PRINCIPAL_INVESTIGATOR)
Marshall HealthHuntingtonWest Virginia25701
Hillary Salava
304-691-6859
Ivan Lopez, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
By specialty

Related Studies